Quoin shareholders approve issuance of shares to Alumni Capital LP

Quoin Pharmaceuticals, Ltd.

Special meeting on April 5, 2024 approved Alumni Issuance Proposal.
Vote: 56,626 for, 23,469 against, 2,338 abstain; no broker non-votes.
Approval allows issuance of up to maximum ordinary shares (ADSs) per Jan 25, 2024 purchase agreement.
Alumni Capital LP is the counterparty; potential dilution from new share issuance.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Quoin Pharmaceuticals, Ltd. shareholders approved approve the issuance of the maximum number of the Company’s ordinary shares represented by ADSs issuable pursuant to the purchase agreement with Alumni Capital LP at the 2024-04-05 meeting.

Outcome: passed
Meeting: 2024-04-05

Exact text from the filing

The shareholders approved the Alumni Issuance Proposal. The results of the voting for this proposal were as follows: For Against Abstain Broker Non-Votes 56,626 23,469 2,338 0

View on SEC.gov

303 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Quoin Pharmaceuticals, Ltd. filing history →

Source: SEC EDGAR

accession 0001104659-24-045210

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.